Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-label, Multi-center Study of Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (mUM) With Integrated Circulating Tumor DNA (ctDNA) Biomarker (TARGET-tebe)

NCT06070012 is registered in ClinicalTrials.gov with Diwakar Davar as lead sponsor.

NCT NCT06070012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06070012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-label, Multi-center Study of Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (mUM) With Integrated Circulating Tumor DNA (ctDNA) Biomarker (TARGET-tebe)
Lead sponsor
Diwakar Davar
Phase
Phase 2
Overall status
Recruiting
Start date
August 18, 2025
Completion date
September 30, 2030
Enrollment
44 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

uveal melanoma